Robert M. Rifkin, Stephanie A. Gregory, Ann Mohrbacher and Mohamad A. Hussein Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma Cancer 106
Article first published online: 10 JAN 2006 | DOI: 10.1002/cncr.21662
The regimen of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone (DVd) was compared with vincristine, doxorubicin, and reduced-dose dexamethasone (VAd) for patients with newly diagnosed multiple myeloma and demonstrated similar efficacy with less toxicity and supportive care compared with VAd. The DVd regimen should improve clinical utility and potentially may optimize the opportunity for transplantation.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.